Loading patent…
AssigneeThe University of Queensland
InventorsMatthew Sweet, Kaustav Das Gupta, Divya Ramnath, Chengzhong Yu, Yue Wang
Estimating the term…
Disclosed are agents, compositions and methods for treating, reducing or inhibiting, or slowing the progression of, unwanted or undesirable immune responses including pro-inflammatory responses. More particularly, the present disclosure relates to a therapeutic agent, therapeutic combinations and their use in compositions and methods for inhibiting or reducing pro-inflammatory activity of immune cells such as antigen-presenting cells (APC), wherein the therapeutic agent comprises D-ribulose-5-phosphate (RL5P), a RL5P analog, a RL5P analog-producing agent and/or a RL5P-producing agent, such as one selected from 6-phosphogluconate dehydrogenase (6PGD) and a nucleic acid molecule from which 6PGD is producible, and wherein the therapeutic combination comprises the therapeutic agent and an HDAC7-producing agent.
A method for inhibiting or reducing pro-inflammatory activity of an antigen-presenting cell, the method comprising contacting the antigen-presenting cell with a therapeutic agent, the therapeutic agent comprising D-ribulose-5-phosphate (RL5P), and/or a RL5P-producing agent, wherein, when present, the RL5P-producing agent is 6-phosphogluconate dehydrogenase (6PGD), or a nucleic acid molecule from which 6PGD is producible.
(canceled)
-8. (canceled)
A therapeutic agent comprising D-ribulose-5-phosphate (RL5P) and/or a RL5P-producing agent wherein, when present, the RL5P-producing agent is 6-phosphogluconate dehydrogenase (6PGD), or a nucleic acid molecule from which 6PGD is producible.
(canceled)
-21. (canceled)
(canceled)
Dependencies are inferred from the claim text.